Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease;Prädiktiver wert der thyreotropinrezeptor-antikörper bei bestimmung im TRAK-human-assay der zweiten generation nach radioiodtherapie des morbus basedow

NuklearMedizin

Volumn 42, Issue 2, 2003, Pages 63-70

  Zöphel, Klaus ^a   Wunderlich, G ^a   Kopprasch, C ^a   Koch, R ^a   Franke, W G ^a   Kotzerke, J ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Graves' disease; Radioreceptorassay; Thyroid autoantibodies; Thyrotropin receptor antibodies; TSH receptor

Indexed keywords

IODINE 131; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DETERMINATION; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; IMMUNOASSAY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROBABILITY; RADIOIMMUNOTHERAPY; RADIOIODINATION; RELAPSE; ROC CURVE; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SWINE; THYROTROPIN RECEPTOR ANTIBODY ASSAY;

EID: 0142256684     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625298     Document Type: Article

References (38)

1. Becker W. Radioiodtherapie des Morbus Basedow. In: Meng W, Pinchera A (Hrsg). Autoimmune Hyperthyreose. Berlin, Wien: Blackwell 1998, 41-9.
2. Bolton J, Sanders J, Oda Y et al. Measurement of thyroid-stimulating hormone receptor auto-antibodies by ELISA. Clin Chem 1999; 45: 2285-7.
3. Börner AR, Voth E, Wienhard K et al. F-18-FDG-PET der Schilddrüse bei Morbus Basedow. Nuklearmedizin 1998; 37: 227-33.
4. Bülow Pedersen I, Knudsen N, Perrild H et al. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol 2001; 55: 381-90.
5. Costagliola S, Morgenthaler NG, Hoermann R et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 1999; 84: 90-7.
6. Dietlein M, Dressler K, Joseph B et al. Leitlinien zur Schilddrüsendiagnostik. Nuklearmedizin 1999; 38: 215-8.
7. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long-term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994; 78: 98-102.
8. Kakinuma A, Morimoto I, Kuroda T et al. Comparison of recombinant human thyrotropin receptors versus porcine receptors in the thyrotropin binding inhibition assay for thyrotropin receptor autoantibodies. Thyroid 1999; 9: 849-55.
9. Massart C, Orgiazzi J, Maugendre D. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Clin Chim Acta 2001; 304: 39-47.
10. Maugendre D, Massart C. Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol 2001; 54: 89-96.
11. Meller J, Schreivogel I, Bergmann A et al. Klinische Implikationen eines neuen TSH-Rezeptor-Antikörper-Assays (DYNOtest®TRAKhuman) bei autoimmunen Schilddrüsenerkrankungen. Nuklearmedizin 2000; 39: 5-9.
12. Meller J, Jauho A, Hüfner M et al. Disseminated thyroid autonomy or Graves' disease: Reevaluation by a second generation TSH receptor antibody assay. Thyroid 2000; 10: 1073-9.
13. Michelangeli V, Poon C, Taft J et al. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8: 119-24.
14. Müller SP. Reiners Chr. Untersuchungen und Empfehlungen zum Design von ROC-Studien in der Nuklearmedizin. Nuklearmedizin 1995; 34: 24-31.
15. 131J-Therapie mit 150 Gy beim Morbus Basedow. Nuklearmedizin 1997; 36: 81-6.
16. Rees Smith B, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev 1988; 9: 106-21.
17. Reiners C. Radiojodtherapie des M. Basedow und der funktionellen Autonomie: state of the art. In: Reinwein D, Weinheim B (Hrsg). Therapie der Hyperthyreose. Berlin, New York: Walter de Gruyter 1994, 117-23.
18. Rink T, Holle LH, Schroth HJ et al. Individuelle Verlaufskontrolle der TSH-Rezeptor-Antikörper-Titer zur Einschätzung der Prognose eines M. Basedow. Nuklearmedizin 1998; 37: 90-4.
19. Rink T, Wieg C, Schroth HJ et al. Frühgeborenenhyperthyreose durch diaplazentar übertragene TSH-Rezeptor-Antikörper der Mutter. Nuklearmedizin 1999; 38: 156-9.
20. Sabri O, Schulz G, Zimny M et al. Bestimmung van Einflussgrößen far den Therapieerfolg der Radioiodtherapie bei Patienten mit Morbus Basedow. Nuklearmedizin 1998; 37: 83-9.
21. Sabri O, Zimny M, Schulz G et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84: 1229-33.
22. Sabri O, Zimny M, Schreckenberger M et al. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999; 9: 1181-8.
23. Sabri O, Zimny M, Schreckenberger M et al. Charakterisierung von Therapieversagern bei der Radioiodtherapie des Morbus Basedow ohne simultane Thyreostase. Nuklearmedizin 2001; 40: 1-6.
24. Sabri O, Zimny M, Ball U. Influence of antithyroid drugs on the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre. Eur J Nucl Med Mol Imaging 2002; 29: 160-1.
25. 125I-labelled TSH receptor. J Clin Endocrinol Metab 1999; 84: 3797-802.
26. Scheidhauer K, Odatzidu L, Kiencke P et al. Körpergewichtsentwicklung nach Radioiodtherapie einer Hyperthyreose. Nuklearmedizin 2002; 41: 47-51.
27. Schleusener H, Schwander J, Fischer C et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 689-701.
28. Schicha H, Dietlein M. Morbus Basedow und Autonomie - Radioiodtherapie. Nuklearmedizin 2002; 41: 63-70.
29. Schott M, Feldkamp J, Bathan C et al. Detecting TSH-receptor antibodies with the recombinant TBII assay: Technical and clinical evaluation. Horm Metab Res 2000; 32: 429-35.
30. Shewring G, Rees Smith B. An improved radioreceptor assay for TSH receptor antibodies. Clin Endocrinol (Oxf) 1982; 17: 409-14.
31. Southgate K, Creagh F, Teece M et al. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin Endocrinol 1984; 20: 539-43.
32. Urbannek V, Voth E, Moka D et al. Radioiodtherapie des Morbus Basedow - dosimetrischer Vergleich verschiedener Therapieregime bezüglich der Thyreostatikagabe. Nuklearmedizin 2001; 40: 111-5.
33. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15: 788-830.
34. Weigand A, Hinzpeter B, Schicha H. Verschlechterung einer endokrinen Orbitopathie nach Radioiodtherapie bei M. Basedow? Nuklearmedizin 1998; 37: 234-8.
35. Zakarija M, McKenzie JM. The spectrum and significance of autoantibodies reacting with the thyrotropin receptor. Endocrinol Metab Clin North Am 1987; 16: 343-63.
36. Zimmermann-Belsing T, Nygaard B, Rasmussen ÅK et al. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol 2002; 146: 173-7.
37. Zöphel K, Wunderlich G, Koch R et al. Die Bestimmung von Thyreotropin-Rezeptor-Antikörpern (TRAK) mit einem Assay der zweiten Generation bei Patienten mit Morbus Basedow. Nuklearmedizin 2000; 39: 113-20.
38. Zweig MH, Campbell G. Receiver-operating characteristic ROC plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77.